6 Questions
What is the primary outcome measured in this study?
Mean change in hemoglobin A1c (HbA1c)
How many participants were randomly assigned to receive either of the treatment regimens?
236 participants
What is the duration of this clinical study?
18 weeks
What is the dosing regimen for dapagliflozin in both combination therapies?
10 mg
Which combination therapy showed a more significant reduction in HbA1c compared to the other?
Dapagliflozin/linagliptin
What is the target HbA1c level achieved by some participants in this study?
Less than 7.0%
This quiz assesses your understanding of a clinical study comparing the efficacy of combination therapy of dapagliflozin plus linagliptin versus dapagliflozin plus vildagliptin in patients with type 2 diabetes. It evaluates your knowledge of the study's methodology and results. Test your knowledge of diabetes management and treatment options.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
